Hukyndra

Hukyndra is a prescription medication that contains the active ingredient adalimumab, a monoclonal antibody, supplied as a subcutaneous injection solution. It is marketed in the European Union and is classified as a TNF‑alpha inhibitor immunosuppressant. The product is administered by injection under the skin and is used to manage several chronic inflammatory conditions. Its formulation does not include a fixed milligram strength in the public data.

Hukyndra is indicated for the treatment of several immune‑mediated inflammatory diseases approved in the EU.

- Rheumatoid arthritis - Psoriatic arthritis - Ankylosing spondylitis - Inflammatory bowel disease (Crohn's disease and ulcerative colitis) - Plaque psoriasis - Hidradenitis suppurativa

Adalimumab may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Injection‑site pain, redness, or swelling - Upper respiratory tract infections (e.g., sinusitis, nasopharyngitis) - Headache

Serious: - Severe infections such as tuberculosis or bacterial sepsis - Malignancies including lymphoma or skin cancer - Neurologic disorders such as demyelinating disease or optic neuritis

Before initiating Hukyndra, clinicians should evaluate several safety considerations to minimize risk.

- Screen for latent tuberculosis and treat before starting therapy - Assess for active infections and postpone treatment if present - Review history of malignancy, especially lymphoma - Monitor for signs of heart failure or worsening cardiac function - Evaluate hepatitis B status and vaccinate if needed - Use caution in pregnancy and lactation due to limited data - Conduct regular laboratory monitoring (CBC, liver enzymes)

Adalimumab can interact with other medicines, influencing efficacy or safety.

Avoid: - Live vaccines (e.g., measles, varicella) because of reduced immune response

Use with caution: - Other immunosuppressants (e.g., azathioprine, methotrexate) may increase infection risk - Cytokine‑targeted therapies (e.g., abatacept, rituximab) may have additive immunosuppression - Antifungal or antibacterial agents that affect immune function - Concomitant use of non‑live vaccines may have reduced effectiveness